Drugs / Carisbamate
Carisbamate
also known as
RWJ-333369 · S-carisbamate · [S]-2-O-carbamoyl-1-o-chlorophenyl-ethanol · Carisbamato · CRS · JNJ-10234094 · RWJ-333369-000 · YKP509
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04520360 | Aug 2020 → Oct 2021 | — | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04062981 | May 2019 → Dec 2022 | Lennox-Gastaut syndrome | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03731715 | Feb 2019 → May 2022 | Lennox-Gastaut syndrome | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT00870454 | May 2009 → Dec 2010 | diabetic polyneuropathy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00524056 | Aug 2007 → Mar 2008 | essential tremor | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00492323 | Mar 2007 → Jun 2008 | herpes zoster, postherpetic neuralgia | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00501202 | Mar 2007 → May 2008 | diabetic polyneuropathy, mononeuropathy, neuropathy, painful | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00210522 | May 2005 → Jun 2010 | focal epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00228969 | Feb 2005 → May 2006 | epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00210652 | Jul 2004 → Mar 2010 | focal epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00109083 | Mar 2002 → Feb 2006 | migraine disorder | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT05219617 | Apr 2022 → Feb 2027 expected | Lennox-Gastaut syndrome | SK Life Science, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT00740623 | Jan → Oct 2009 | complex partial epilepsy, partial motor epilepsy, simple partial epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00744731 | Jan 2009 → Aug 2010 | complex partial epilepsy, partial motor epilepsy, simple partial epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00697918 | Mar 2008 → Apr 2009 | epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00563459 | Nov 2007 → Apr 2010 | epilepsy | SK Life Science, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00697762 | Oct 2007 → May 2008 | epilepsy | SK Life Science, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00991757 | Feb 2007 → Oct 2010 | complex partial epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00425282 | Nov 2006 → Oct 2007 | complex partial epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00433667 | Nov 2006 → Oct 2007 | complex partial epilepsy | SK Life Science, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02435381 Comparator | Feb → Sep 2013 | alcohol abuse, alcohol dependence | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carisbamate | “BACKGROUND: Carisbamate ([S]-2-O-carbamoyl-1-o-chlorophenyl-ethanol; RWJ 333369) is a new chemical entity being studied for efficacy as adjunctive therapy in partial onset epilepsy.” PMID 19222595 ↗ Feb 200915“Patients electing to enter the open-label extension phase will be supplied with both open-label carisbamate (RWJ-333369) and blinded study medication for the transition phase.” NCT00210522 ↗ “patients will transition through a blinded period to an open-label period with carisbamate (also referred to as RWJ-333369).” NCT00210652 ↗ “RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks” NCT00501202 ↗ |
| Known as | [S]-2-O-carbamoyl-1-o-chlorophenyl-ethanol | “BACKGROUND: Carisbamate ([S]-2-O-carbamoyl-1-o-chlorophenyl-ethanol; RWJ 333369) is a new chemical entity being studied for efficacy as adjunctive therapy in partial onset epilepsy.” PMID 19222595 ↗ Feb 2009 |
| Known as | Carisbamato | ChEMBL registry synonym — accepted as the source's own label CHEMBL2087003 ↗ |
| Known as | CRS | “OBJECTIVE: To evaluate the efficacy, safety, and tolerability of carisbamate (CRS), an investigational drug, as adjunctive treatment for partial-onset seizures in adults.” PMID 19001248 ↗ Nov 2008 |
| Known as | JNJ-10234094 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2087003 ↗ |
| Known as | RWJ-333369 | “BACKGROUND: Carisbamate ([S]-2-O-carbamoyl-1-o-chlorophenyl-ethanol; RWJ 333369) is a new chemical entity being studied for efficacy as adjunctive therapy in partial onset epilepsy.” PMID 19222595 ↗ Feb 200912“Patients electing to enter the open-label extension phase will be supplied with both open-label carisbamate (RWJ-333369) and blinded study medication for the transition phase.” NCT00210522 ↗ “patients will transition through a blinded period to an open-label period with carisbamate (also referred to as RWJ-333369).” NCT00210652 ↗ “patients will transition through a blinded period to an open-label period with carisbamate (also referred to as RWJ-333369).” NCT00991757 ↗ |
| Known as | RWJ-333369-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2087003 ↗ |
| Known as | S-carisbamate | “An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)” NCT04062981 ↗1“An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)” NCT03731715 ↗ |
| Known as | YKP509 | “The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic)...” NCT05219617 ↗ |
| Action | Inhibit | “inhibits voltage-gated sodium channels” PMID 34870321 ↗ Dec 2021 |
| Modality | Small molecule | “is a new chemical entity” PMID 19222595 ↗ Feb 2009 |
| Route | Oral | “RWJ-333369 (100, 300, 800, or 1,600 milligrams per day) administered orally” NCT00210522 ↗ |